FierceBiotech by Conor Hale,
Concerto HealthAI has inked its second real-world data collaboration with a Big Pharma company in as many weeks, this time to help Pfizer select patients for its precision oncology development work.
Concerto, a SymphonyAI company, aims to design more efficient clinical trials using prefabricated control arms and data from electronic medical records and insurance claims, as well as economic outcome measures, all through the use of artificial intelligence and machine learning.
In late March, the company signed on to a multi-year project with Bristol-Myers Squibb focusing on a range of different cancers. At Pfizer, the work will cover investigational and approved treatments, across both solid and blood tumors.
It is reported that the project will also look to identify new patient subpopulations for combination cancer therapy trials and includes plans to design and conduct real-world outcomes studies using synthetic control arms, with the first results expected early next year.